araag2/HINT huggingface dataset:
Clinical trial NCT01046461 (phase 2, status: unknown status)
Conditions: solid tumour, postoperative nausea and vomiting
ICD codes: R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: ramosetron, aprepitant, dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  18 -75 years, both sex

          -  ECOG performance status 0-2

          -  Histologically proven solid cancer, chemotherapy-naïve patient

          -  Planed to receive cisplatin (≥ 50mg/m2) based, single day chemotherapy,

          -  No nausea or vomiting within 72 hours prior to chemotherapy

          -  Serum Cr < 2.5 mg/dl, or calculated CCr ≥ 50 ml/min

          -  Serum total bilirubin < 2 mg/dl, AST/ALT < 3 times the upper normal limit , ALP < 5
             times the upper normal limit

          -  Absolute neutrophil count ≥ 1,500/μL, platelet ≥ 100,000/μL

          -  Expected life duration ≥ 3 months

          -  Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study in keeping with the policy of the hospital

        Exclusion Criteria:

          -  Patients with active infection, severe heart disease, uncontrollable hypertension or
             diabetes mellitus, active gastric or duodenal ulcers, or pregnancy or breast-feeding

          -  Patients who should take steroid, antiemetics, pimozide, terfenadine, astemizole,
             cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone,
             troleandomycin, clarithromycin, ritonavir or nelfinavir for the treatment of other
             diseases

          -  Patients taking any medicine, which could affect study results, within 1 week before
             chemotherapy (or taking anti-emetics within 48 hours before chemotherapy). Prior to
             beginning chemotherapy, single-agent benzodiazepines as hypnotic is allowed, but it
             can't be receiving during day 1-6 of 1st chemotherapy cycle.

          -  Patients with symptomatic brain metastasis

          -  Patients with GI obstruction or other diseases that could provoke nausea and vomiting

          -  Patients receiving RT on brain, abdomen or pelvis within 2 weeks before chemotherapy

          -  Patients who cannot understand informed consent or express his/her condition

          -  Patients who cannot swallow drugs

          -  Patients who have known allergy or severe side effect on study drugs
Clinical trial NCT00072670 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: trabectedin
SMILES: [H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Radiographically documented metastatic disease

          -  Surgical or chemical castration

          -  Prostate-specific antigen greater than or equal to (>=) 5 nanogram per milliliter
             (ng/ml)

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2

          -  Androgen Independent disease

        Exclusion Criteria:

          -  Treatment with chemotherapy or radiation therapy that was terminated at least 4 weeks
             before study entry

          -  Treatment with extensive external beam radiation therapy or radionuclide therapy
             within 6 weeks of study entry (palliative radiation involving less than 20 percent of
             bone marrow reserves must have been completed at least 4 weeks before study entry)

          -  Participant not employing adequate contraception

          -  Other serious illness or medical conditions as : Uncontrolled congestive heart failure
             or history of myocardial infection or active angina pectoris within six months
             preceding registration; active infectious process; chronic active liver disease,
             including chronic Hepatitis B, chronic Hepatitis C, or cirrhosis
Clinical trial NCT00234026 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: gemcitabine hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed mantle cell lymphoma meeting 1 of the following criteria:

               -  Newly diagnosed

               -  Chemotherapy resistant

               -  Relapsed disease after no more than 2 prior lines of chemotherapy

          -  Measurable disease

               -  At least 1 unidimensionally measurable lesion ≥ 11 mm by CT scan

          -  No prior or current CNS lymphoma or lymphomatous meningosis

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Neutrophil count ≥ 1,500/mm^3 (1,000/mm^3 in case of bone marrow infiltration)

          -  Platelet count ≥ 100,000/mm^3 (75,000/mm^3 in case of bone marrow infiltration)

        Hepatic

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2 times ULN

          -  AST and ALT ≤ 2 times ULN

          -  No active hepatitis

        Renal

          -  Creatinine clearance ≥ 50 mL/min

        Cardiovascular

          -  No congestive heart failure

          -  No New York Heart Association class III or IV heart disease

          -  No unstable angina pectoris

          -  No significant cardiac arrhythmia or arrhythmia requiring chronic treatment

          -  No myocardial infarction within the past 3 months

        Immunologic

          -  No active autoimmune disease

          -  No ongoing infection (e.g., HIV)

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 12 months after study
             participation

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             adequately treated carcinoma in situ of the cervix

          -  No uncontrolled diabetes mellitus

          -  No gastric ulcers

          -  No other uncontrolled medical condition that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent thalidomide

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Prior radiotherapy allowed provided indicator lesions were not in the irradiated field

          -  No concurrent radiotherapy to the lungs or mediastinum

        Surgery

          -  Not specified

        Other

          -  More than 30 days since prior systemic anticancer treatment

          -  More than 30 days since prior clinical trial participation

          -  No other concurrent anticancer drugs

          -  No other concurrent experimental drugs
Clinical trial NCT00663260 (phase 2/phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, ≥18 years old, with type 2 diabetes and with inadequate glycemic
             control

          -  Clinical diagnosis of moderate renal impairment

        Exclusion Criteria:

          -  AST and /or ALT > 3.0 times the upper limit of normal

          -  Serum total bilirubin > 1.5 times ULN

          -  Symptoms of severely uncontrolled diabetes

          -  Currently unstable or serious cardiovascular, hepatic, hematological, oncological,
             endocrine, psychiatric, or rheumatic diseases
Clinical trial NCT00216151 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: zoledronic acid
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Reason stopped: 
    study terminated due to low patient enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of asymptomatic multiple myeloma as defined by the criteria below:

          -  Presence of bone marrow clonal plasma cells (more than 10%)

          -  Presence of an M-protein in serum and/or urine (no concentration specified)

          -  Serum calcium < 12 mg/dl within 14 days prior to registration. Less than 3 lytic
             lesions, no pathologic fractures and no osteopenia noted on skeletal survey

          -  No symptoms of hyperviscosity, amyloidosis or recurrent infection

          -  Bone mineral density with a T score higher than -2.0 standard deviation (not have
             osteoporosis) within 28 days prior to registration

          -  Negative pregnancy test

        Exclusion Criteria:

          -  No previous treatment with bisphosphonates

          -  No disorders of the parathyroid or thyroid glands

          -  No current breastfeeding

          -  No prior malignancy is allowed except for adequately treated in situ cervical cancer,
             Gleason < grade 7 prostate cancers
Clinical trial NCT00582790 (phase 2, status: terminated)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: il2, zoledronic acid
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed renal cell carcinoma with metastasis.

          -  Must have measurable disease.

          -  No prior cytokine, chemotherapy, hormonal, or other immuno-based therapies (including
             vaccine or cellular based) for their renal cancer is allowed. No prior use of
             bisphosphonates will be allowed. One prior experimental therapy will be permitted as
             long as > 4 weeks have passed since last drug administration.

          -  ECOG performance status 0 or 1

          -  Adequate cardiac function by history.

          -  Pulse-oximetry > 92% on room air.

        Exclusion Criteria:

          -  Radiotherapy within 4 weeks prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier.

          -  Known brain metastases

          -  Any history of an autoimmune disease (ie. psoriasis, inflammatory bowel disease, etc)
             must receive clearance by the investigator before being permitted on study due to the
             potential worsening of those disorders from IL-

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia.

          -  History of myocardial infarction or hospitalization for congestive heart failure
             within 12 months of enrollment.

          -  History of prior malignancy (except basal cell carcinoma resected with curative
             intent) unless resected or treated with curative intent and disease free for > 5
             years.

          -  Any history of seizures given increased seizure risk with IL-2.

          -  Organ allograft (transplant) recipients will be excluded given absolute
             contraindication with IL-2 therapy.

          -  Pregnant women are excluded

          -  Patients on systemic steroids (oral or IV) will not be eligible for the study.
Clinical trial NCT00548327 (phase 2, status: terminated)
Conditions: schizophrenia, memory disorders, cognition disorders
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, I69.311, I69.011, I69.111, I69.811, I69.911, I69.211, F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5
Drugs: atomoxetine, placebo
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the scientific director decided to terminate: low priority study with slow accrual
  
Eligibility criteria:

        -  INCLUSION CRITERIA:

          -  Prior participation under NIH protocol # 95-M-0150, or new normal volunteers or
             schizophrenic patients that meet criteria for NIH protocol # 95-M-0150.

          -  No active Axis I or Axis II diagnosis in normal volunteers.

          -  Age range: 18-45 years.

          -  Normal EKG and blood pressure readings.

        EXCLUSION CRITERIA:

          -  Normal volunteers with an active Axis I or Axis II disorder or patients with an Axis I
             diagnosis other than schizophrenia or schizoaffective disorder obtained either from
             prior Structured Clinical Interview for the Diagnostic and Statistical Manual
             Disorders (SCID) interview in Protocol 95-M-0150 or through a screening interview will
             be excluded.

          -  Subjects with a history of cardiovascular disease, liver disease and other serious
             medical illnesses, and untreated or uncontrolled hypertension will be excluded because
             of the potential for drug-drug interaction or because of the potential deleterious
             effect of the drug on the medical condition. An electrocardiogram, blood pressure,
             pulse rate, toxicological screen, cell blood count and metabolic panel including Liver
             Function Tests (LFTs) will be checked on all subjects prior to participation in the
             study. Any subject with an electrocardiogram deemed abnormal by a cardiologist or with
             sustained systolic blood pressure of 150 mmHg or above, diastolic blood pressure of
             100 mmHg or above will be excluded from the study.

          -  Schizophrenic patients taking a COMT inhibitor, any illicit drugs of abuse, or
             Monoamine Oxidase (MAO) inhibitors will be excluded. Patients taking paroxetine,
             fluoxetine, bupropion, tricyclic antidepressants, albuterol, modafinil, stimulants or
             pressor agents will be excluded from the study. No medication will be stopped in order
             to participate in the study.

          -  Normal control subjects taking any medication other than occasional nonsteroidal
             anti-inflammatory drugs (NSAID) or with recent history of illicit drug or alcohol
             abuse will be excluded. Normal controls on contraceptive medication will be excluded
             from the study.

          -  Pregnant women: Women of childbearing potential will undergo a urine pregnancy test
             the day the study initiates and they will be screened by history for the possibility
             of pregnancy.
Clinical trial NCT01689571 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: chf6001, placebo
SMILES: CS(=O)(=O)NC1=CC=C(C=C1OCC1CC1)C(=O)O[C@@H](CC1=C(Cl)C=[N+]([O-])C=C1Cl)C1=CC=C(OC(F)F)C(OCC2CC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  written informed consent obtained

          -  Non smoking or ex-smokers from at least 1 year prior to study entry

          -  Males of females between 18 and 60 years inclusive

          -  Body Mass Index between 18 and 32 kg/m2

          -  Ability to be trained about the proper use of the inhalation device and to perform
             spirometry

          -  With mild to moderate allergic asthma as defined by the GINA guideline, steroid naive

          -  Atopy to at least one common aeroallergen

          -  Positive allergen-induced Early Asthmatic Response and Late Asthmatic Response at
             screening

          -  Ability to produce an adequate sputum sample

          -  Post-menopausal women, women of not childbearing potential or males and females of
             childbearing potential willing (they or their partner) to use a reliable method of
             contraception.

        Exclusion Criteria:

          -  Worsening of asthma or respiratory tract infection prior to study entry

          -  History of life-threatening asthma or hospitalization for asthma prior to the study
             entry

          -  Pregnant or lactating women

          -  History of clinically significant hypotensive episodes or fainting, dizziness or
             light-headedness

          -  History or symptoms of clinically relevant neurologic disease

          -  Symptomatic hay fever

          -  Unstable concurrent disease that may impact the feasibility of the study

          -  Use of systemic corticosteroids, nebulised bronchodilator or oral beta2-agonist

          -  Use of leukotrienes modifiers, roflumilast or cromoglycate

          -  Use of long acting beta2-agonist or inhaled corticosteroids

          -  Use of short-acting or long-acting non-sedatives antihistamines

          -  Use of any other medication for the treatment of allergic asthma other than salbutamol

          -  Having received an investigational medicinal drug within 30 days prior to study entry

          -  Blood drawn of at least 250 ml in the previous 45 days

          -  Ongoing use of tobacco

          -  Other lung disease

          -  Recent history of alcohol dependency

          -  Inability to comply with the study protocol
Clinical trial NCT00361153 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: colesevelam hydrochloride, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects meeting the following criteria at the Screening Visit will be eligible to
        participate in the trial:

          -  Have given written informed consent

          -  Ages 18 to 75 years, inclusive

          -  Diagnosis of type 2 diabetes mellitus of at least 3 months duration

          -  HbA1C 7.0- 10.0%, inclusive

          -  Antidiabetic treatment may include oral agents; all antidiabetic agents must be
             withdrawn before randomization

          -  Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening
             Visit), are not breast-feeding, and do not plan to become pregnant during the trial.
             In addition, they must either have had a hysterectomy or tubal ligation at least 6
             months before signing informed consent, be post-menopausal for 1 year, or practicing
             an acceptable method of birth control. An acceptable method of birth control may be
             oral, injectable or implantable hormonal contraceptives, intrauterine device,
             diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use
             of condoms, and partner's vasectomy are NOT acceptable methods of contraception

          -  BMI 25 - 45 kg/M sq, inclusive

        Exclusion Criteria:

        Subjects are excluded from participation in the study if any of the following criteria
        apply:

          -  Type 1 diabetes mellitus or history of diabetic ketoacidosis

          -  Treatment with lipid or blood pressure lowering therapy that has not been stable for
             three months before randomization

          -  Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the
             last 3 months

          -  Treatment with thiazolidinediones

          -  History of dysphagia, swallowing disorders, or intestinal motility disorder

          -  Serum triglyceride >500 mg/dL at Visit 1

          -  Serum LDL-C <60 mg/dL at Visit 1

          -  Any condition or therapy which, in the opinion of the investigator, poses a risk to
             the subject or makes participation not in the subject's best interest

          -  Use of any investigational drug within 30 days before randomization

          -  Chronic treatment with oral corticosteroids

          -  History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine
Clinical trial NCT01639040 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: dupilumab, placebo (for dupilumab)
SMILES: CCO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female patients aged 18 years or older

          2. Chronic AD that had been present for at least 2 years

        Exclusion Criteria:

          1. Prior treatment with Dupilumab

          2. Hypersensitivity to corticosteroids or to any other ingredients contained by the TCS
             product used in the study

          3. AD lesions located on face, flexural, and genital areas

          4. Certain treatments and medical procedures, undertaken within a particular time frame
             prior to the baseline visit, preclude eligibility for participation in the study

          5. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit

          6. Treatment with an investigational drug within 8 weeks

          7. Known history of human immunodeficiency virus (HIV) infection

          8. Presence of certain laboratory abnormalities at the screening visit

          9. History of certain opportunistic infections or certain clinical parasite infections

         10. History of malignancy within 5 years before the baseline visit, with certain
             exceptions

         11. Pregnant or breast-feeding women

         12. Travel within 12 months of study start to areas endemic for parasitic infections, such
             as developing countries in Africa and the tropical and subtropical regions of Asia

         13. History of alcohol or drug abuse within 2 years of the screening visit

         14. Any medical or psychiatric condition which, in the opinion of the investigator or the
             sponsor's medical monitor, would place the patient at risk, interfere with
             participation in the study, or interfere with the interpretation of study results